Growth/differentiation factor 15 causes TGFβ-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertension. Issue 2 (15th December 2018)

• Record Type: Journal Article
• Authors: Garfield, Benjamin E; Crosby, Alexi; Shao, Dongmin; Yang, Peiran; Read, Cai; Sawiak, Steven; Moore, Stephen; Parfitt, Lisa; Harries, Carl; Rice, Martin; Paul, Richard; Ormiston, Mark L; Morrell, Nicholas W; Polkey, Michael I; Wort, Stephen John; Kemp, Paul R
• Is Part Of: Thorax. Volume 74:Issue 2(2019)
• Page Start: 164
• Page End: 176
• Publication Date: 2018-12-15
• Subjects: primary pulmonary hypertension -- exercise; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2017-211440
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: Skeletal muscle dysfunction is a clinically important complication of pulmonary arterial hypertension (PAH). Growth/differentiation factor 15 (GDF-15), a prognostic marker in PAH, has been associated with muscle loss in other conditions. We aimed to define the associations of GDF-15 and muscle wasting in PAH, to assess its utility as a biomarker of muscle loss and to investigate its downstream signalling pathway as a therapeutic target. Methods: GDF-15 levels and measures of muscle size and strength were analysed in the monocrotaline (MCT) rat, Sugen/hypoxia mouse and in 30 patients with PAH. In C2C12 myotubes the downstream targets of GDF-15 were identified. The pathway elucidated was then antagonised in vivo. Results: Circulating GDF-15 levels correlated with tibialis anterior (TA) muscle fibre diameter in the MCT rat (Pearson r=−0.61, p=0.003). In patients with PAH, plasma GDF-15 levels of <564 pg/L predicted those with preserved muscle strength with a sensitivity and specificity of ≥80%. In vitro GDF-15 stimulated an increase in phosphorylation of TGFβ-activated kinase 1 (TAK1). Antagonising TAK1, with 5(Z)-7-oxozeaenol, in vitro and in vivo led to an increase in fibre diameter and a reduction in mRNA expression of atrogin-1 in both C2C12 cells and in the TA of animals who continued to grow. Circulating GDF-15 levels were also reduced in those animals which responded to treatment. Conclusions: Circulating GDF-15 is a biomarker of muscle loss in PAH that is responsive to treatment. TAK1 inhibition shows promise as a method by which muscle atrophy may be directly prevented in PAH. Trial registration number: NCT01847716 ; Results.